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In vitro susceptibility studies of 246 clinical isolates demon-
strated that this antibiotic was effective against Group A beta 
hemolytic streptococci, alpha hemolytic streptococci, S. 
pneumoniae, both penicillinase producing and non-
penicillinase producing Staphylococci, Klebsiella pneu-
moniae, and Proteus mirabilis. Cephalothin susceptible E. 
coii were also susceptible to cefaclor. Pseudomonas 
aeruginosa, Serratia sp., Enterobacter Sp., and Streptococ-
cus faecalis were uniformly resistant to cefaclor. The 
efficacy and safety of this antibiotic were studied in 27 
patients with urinary tract, soft tissue, and respiratory infec-
tions. Patients with urinary tract infections became abac-
teriuric after 48 hours. Patients with soft tissue infections 
responded well within the first week of therapy, and throat 
cultures of patients with tonsillitis were negative ten days 
and six weeks after treatment. The drug was well tolerated, 
and no significant adverse effect was noted. 
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Cefac lo r is a new, semisynthetic oral cephalosporin, struc-
turally related to cephalexin. It is well absorbed, with no 
significant side effects,^ and is more active than cephalexin 
against most of the susceptible organisms.^ ' This report 
deals with 1) the pharmacology, effectiveness, and tolerance 
of cefaclor in treating 27 patients with infections caused by 
susceptible pathogens and 2) the in vitro susceptibility of 
representative clinical isolates. Clinical observations were 
made at Henry Ford Hospital and compared with our earlier 
results with cephalexin.''^ 
Materials and Methods 
Laboratory studies 
The susceptibility to cefaclor of 246 strains of gram-positive 
and gram-negative isolates was determined by agar dilution 
method with Mueller-Hinton agar (BBL), except for beta 
hemolytic streptococci, to which blood was added.^'^ Anti-
biotics were added to the media at 50°C to avoid antibiotic 
degradation. Approximately 10' organisms were added to 
the media. The minimum inhibitory concentration (MIC) 
was defined as the lowest concentration that inhibited 
bacterial growth after 18 hours of incubation at 37°C. The 
susceptibilities of the following bacteria were determined: 
£. co//, Proteus mirabilis, Enterobacter sp., indole positive 
Proteus, Serratia sp., staphylococci. Group A beta hemolytic 
streptococci alpha streptococci,Streptococcus faecalis, and 
Streptococcus pneumoniae. 
Serum concentrations from 19 patients and volunteers were 
determined by disc plate assay' using6ac///us subt///s (ATCC 
6633) as the test organism. 
Concentrations were determined at 1, 2, 3, 4, and 6 hours 
after 250 mgand 500 mg of cefaclor had been administered 
orally. The patients had received it for at least 24 hours when 
the serum specimens were obtained. 
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Clinical studies 
The antibiotic was administered orally to 27 patients with 
urinary tract infections, skin infections, bacterial phar-
yngitis, and pneumonia due to susceptible organisms. Eight 
patients were given 750 mg per day, 10 patients were given 
1000 mg per day, and 9 were given 2 gm perday for 7 to 10 
days. Periodic clinical examinations were performed and 
appropriate cultures were obtained before, during, and after 
treatment. Safety studies included evaluations of renal, 
hepatic and hematologic functions before, during and after 
antibiotic administration. Patients were followed for six 
weeks after treatment whenever possible. 
Results 
Antimicrobial activity 
The in vitro activity of cefaclor and its comparison with 
cephalexin and cephalothin are shown in Figures 1-9. 
Cefaclor was considerably more active than cephalexin 
against all gram-positive organisms tested, including Group 
A beta hemolytic streptococci andS. pneumoniae. Cefaclor 
was less active against both penicillinase-producing and 
n o n p e n i c i l l i n a s e - p r o d u c i n g s t a p h y l o c o c c i than 
cephalothin (Figures 1-5). On the other hand, all 23 strains of 
entero cocci were resistant to all three antibiotics, although 
for cefaclor the MIC was only 25 ju,g per ml and for 
cephalexin and cephalothin, 50 /u,g/ ml. 
Cefaclor was the most active of the three against £. coii, K. 
pneumoniae, and P. mirabilis (Figures 6-8). Only 10% ofthe 
strainsof Enterobacter sp. were inhibited by 25 mg per ml or 
less of cefaclor, and lessthan 5% of strains were inhibited by 
the same concentration of cephalexin and cephalothin 
(Figure 9). Al l strains of indole posit ive proteus (13), 
Pseudomonas aeruginosa (20), and Serratia sp. (12) were 
uniformly resistant to all three antibiotics tested with MICs 
greater than 50 pg per ml. 
TABLE 1 
Serum Concentration 
Of Cefaclor and Cephalexin 
Hours After Dose Cefaclor Cephalexin* 
250 mg Orally meg/ ml meg 'ml 
1/2 4,5 5,7 
1 5,6 10,9 
2 1,75 4.9 
3 1.0 
-
4 
-
I.C 
5 
- -
6 
-
0.6 
Serum concentrations 
After 250 mg of cefaclor, the mean peak serum concentra-
tion was 5.6 /i.g per ml; at the end of three hours the 
concentration decreased to 1 pg per ml or less. Similar 
results were obtained with the 500 mg oral dose after three 
hours. Compared to cephalexin (Table I), the concentrations 
were slightly less and less sustained. 
CEFACLOR • • 
CEPHALOTHIN 
• — _ _ — — . s 
CEPHLEXIN 
>0.025 0.025 0.05 O.l 0.2 0.4 0.8 
MIC ( p.g /ml) 
Flg.1 
Susceptibility of 33 strains of Group A Beta hemolytic streptococcus. 
CEPHALOTHIN 
•0.025 
I I I 
0.025 0.05 O.l 0.2 0.4 3.2 6.4 
Fig. 2 
Susceptibility of 20 strains ot Streptococcus pneumoniae. 
' After Cox, et al 
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2.8 25.6 
Fig. 3 
Susceptibility of 20 strains of alpha streptococcus. 
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Fig. 5 
Susceptibility of 18 strains of penicillinase-producing Staphylococcus 
aureus. 
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Fig. 4 
Susceptibility of 20 stramsof nonpenicillinase-producing Sfap/iyfococcus 
aureus. 
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• 
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12.8 25.6 50,0 
Fig. 6 
Susceptibility of 15 strains off. coii. 
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CEPHALOTHIN • • 
CEPHALEXIN 
0.2 0.4 0.8 .6 3 2 6.4 12.8 25.6 50,0 
MIC ( / xg /m l ) 
Fig. 7 
Susceptibility of 17 strains of Klebsiella sp. 
Clinical results 
Cefaclor was administered to 27 patients with culture-
proved urinary tract, soft tissue, and respiratory infections 
caused by susceptible pathogens (Table II). Among these 
patients, 16 had urinary tract infections, six had soft tissue 
infections, and five had respiratory infections. Eleven pa-
tients with £. coll urinary tract infections were treated, and 
10 became abacteriuric in 48 hours. In one patient, despite 
clinical improvement, the antibiotic was stopped because of 
reported resistance ofthe organism to cefaclor by the disc 
method. Three patients with K/ebs/e/Za pneumoniae urinary 
tract infection were treated, and two became abacteriuric in 
48 hours. However, one patient who had lower urinary tract 
obstruction secondary to prosatic hypertrophy continued to 
show significant bacteriuria and required parenteral gen-
tamicin and transurethral resection of the prostate for cure. 
One patient with Proteus mirabilis bacteriuria and one 
symptomatic patient with multiple positive urine cultures 
ior Staphylococcus epidermidis were treated and cured with 
this antibiotic. There was no reinfection by other organisms 
and only one recurrence by the same organism nine days 
after treatment had been completed. Eight of 16 patients 
received 250 mgevery 8 hours, andthe rest received 250 mg 
every 6 hours for 7-10 days. 
Six patients were treated for soft tissue infection and ab-
scesses. Among these, four with acute Staphylococcus 
aureus infections improved on therapy, but the antibiotic 
had to be stopped after three and five days in two of them 
because of side effects (nausea and vomiting in one and 
diarrhea in one); both were drug abusers. One patient with 
mixed Staphylococcus aureus and Group A beta hemolytic 
streptococcus was treated and cured with cefaclor 500 mg 
every 6 hours. Clinical improvement was seen also in 
another patient with polymicrobial infection due to E. coii, 
A. hydrophila, and Enterobacter sp., but cultures continued 
to grow Enterobacter sp. 
Five patients who received cefaclor for respiratory tract 
infections were all cured and had negative follow-up cul-
tures. Four of these patients had acute tonsillitis due to 
Group A beta hemolytic streptococcus and one patient had 
lobar pneumonia due to Streptococcus pneumoniae. 
No major adverse reactions were observed with cefaclor 
treatment. In two parenteral drug abusers, nausea, vomiting 
and diarrhea were noted, but it was hard to distinguish those 
symptoms from narcotic withdrawal symptoms. All serum 
chemistries, including SCOT, SGPT, alkaline phosphatase, 
bilirubin, serum creatinine and blood urea nitrogen, were 
normal before, during, and after treatment, except for mild 
transientelevationof SCOT in one patient. Coomb's test was 
also negative in all patients. Mild eosinophilia was noted in 
two patients. 
TABLE II 
Results of Treatment of 27 Patients with Cefaclor 
Results 
Diseases and No. of Cases Organisms Good Fair Poor 
Urinary Tract Infect ion (16) Escherichia coii 10 1 -
Klebsiella pneumoniae 2 
-
1 
Proteus mirabilis 1 
- -
Staphylococcus epidermidis 1 
- -
Soft Tissue Infect ions (6) Staphylococcus aureus 2 2 
-
Staph, aureus -f beta hemolyt ic 
s t reptococci g roup A 1 
- -
E. coii + Enterobacter sp. -\-
A. hydrophila 
-
1 
-
Respiratory Tract Infect ion (5) 
Pneumonia (1) Streptococcus pneumoniae 1 
- -
Tonsi l l i t is (4) Beta Streptococc i Group A 4 
- -
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CEFACLOR • • 
CEPHALOTHIN 
• — —— • 
CEPHALEXIN 
0.4 0.8 1.6 3,2 6.4 12.8 25.6 
MIC ( / x g / m l ) 
Fig. 8 
Susceptibility of 20 strains of Proteus mirabilis. 
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Fig. 9 
Susceptibility of 13 strains of Enterobacter sp. 
Discussion 
Cefaclor is a new, semisynthetic oral cephalosporin related 
to cephalexin. It has wide spectrum of activity, and the 
earlier reports^"® indicated greater in vitro activity against 
more of the gram-positive bacteria and all ofthe susceptible 
gram-negative bacteria when it was compared with other 
available oral cephalosporins. Against penicillinase-pro-
ducing and nonpenicillinase-producing Staphylococcus 
aureus, cefaclor was more active than cephalexin but less 
than cephalothin,"'^^ Against different species of strep-
tococc i , it was at least four times more active than 
cephalexin."'" Cefaclor was uniformly more active than 
cephalexin and other oral or parenteral cephalosporins 
against susceptible gram-negative organisms, including 
Hemaphilus isolates.^'^'H'i^ Animal studies^'''^ showed that 
this drug is well absorbed orally with a peak of 5.8 to 6.9 pg 
per ml after a single dose of 250 mg. Our study revealed a 
one-hourconcentrationof5.6/Agperml and lessthanO.1 pg 
per ml after four hours. This concentration is slightly lower 
and less sutained''" than cephalexin, but better results in 
therapy of experimental animalscan beexplained by higher 
activity against almost all susceptible organisms. Strep-
tococcus faecalis, indole positive Proteus, Serratia sp., and 
Pseudomonas aeruginosa were all uniformly resistantto this 
antibiotic in our study, as was also shown in earlier reports. 
Although enterobacter species were slightly more suscepti-
ble to cefaclor than cephalexin and cephalothin, only 
10-30% ofthe strains have been shown to be susceptible to 
cefaclor.^"® 
Although clinical trial of cefaclor is limited,^^'^^ in our study 
26 of 27 infections were cured or showed significant 
symptomatic improvement. Bacteriuria recurred in one 
patient nine days after therapy had been completed. One 
patient with urinary tract infection failed on therapy, al-
though obstructive uropathy might account for this failure. 
He also failed on cephalexin, co-trimoxazole, and amox-
acillin. Cefaclor was as effective as amoxacillin in treating 
lower urinary tract infections in w o m e n , I n softtissue and 
respiratory tract infections, all patients but one were cured. 
The one exception was a patient with polymicrobial infec-
tion secondary to drug abuse who had a continued positive 
culture for enterobacter sp. 
In our study, cefaclor was well absorbed orally and almost all 
was excreted by the kidney It was also wel I tolerated, except 
for two patients who had gastrointestinal side effects. No 
significant hematologic or hepatic dysfunctions were noted. 
Experimental animal studies have confirmed the safety of 
this antibiotic. Large doses of cefaclor administered to 
animals produced minimal changes in serum with transient 
changes in hemoglobin and platelets." 
In conclusion, cefaclor is a wide spectrum antibiotic shown 
to be well absorbed and well tolerated. It is more active in 
vitro than cephalexin against all common gram-positive and 
gram-negative organisms tested, and when administered 
orally, it is effective against infections caused by susceptible 
organisms. 
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